Bank of New York Mellon
CRBP icon

Bank of New York Mellon’s Corbus Pharmaceuticals CRBP Stock Holding History

Bank of New York Mellon’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$425K Buy
+45,282
New +$429K ﹤0.01% 3818
2025
Q2 		– Sell
-23,206
Closed -$123K – 4161
2025
Q1 		$123K Sell
23,206
-1
-0% -$9 ﹤0.01% 3973
2024
Q4 		$274K Sell
23,207
-1,069
-4% -$17.9K ﹤0.01% 3826
2024
Q3 		$501K Sell
24,276
-5,960
-20% -$305K ﹤0.01% 3517
2024
Q2 		$1.37M Buy
+30,236
New +$1.27M ﹤0.01% 3010
2023
Q1 		– Sell
-1,069
Closed -$3.54K – 4395
2022
Q4 		$3.54K Sell
1,069
-74
-6% -$285 ﹤0.01% 4457
2022
Q3 		$5K Hold
1,143
– – ﹤0.01% 4535
2022
Q2 		$9K Hold
1,143
– – ﹤0.01% 4555
2022
Q1 		$18K Hold
1,143
– – ﹤0.01% 4621
2021
Q4 		$21K Hold
1,143
– – ﹤0.01% 4582
2021
Q3 		$35K Sell
1,143
-5,431
-83% -$214K ﹤0.01% 4476
2021
Q2 		$361K Sell
6,574
-2,330
-26% -$129K ﹤0.01% 3911
2021
Q1 		$527K Buy
8,904
+1,357
+18% +$89.2K ﹤0.01% 3659
2020
Q4 		$282K Sell
7,547
-1,546
-17% -$57.8K ﹤0.01% 3853
2020
Q3 		$492K Buy
9,093
+72
+0.8% +$13K ﹤0.01% 3498
2020
Q2 		$2.27M Buy
9,021
+1,757
+24% +$355K ﹤0.01% 2607
2020
Q1 		$1.14M Buy
7,264
+624
+9% +$105K ﹤0.01% 2881
2019
Q4 		$1.09M Buy
6,640
+134
+2% +$19.8K ﹤0.01% 3202
2019
Q3 		$951K Sell
6,506
-498
-7% -$86.7K ﹤0.01% 3206
2019
Q2 		$1.46M Buy
7,004
+137
+2% +$29.3K ﹤0.01% 2991
2019
Q1 		$1.43M Buy
6,867
+388
+6% +$85.6K ﹤0.01% 2958
2018
Q4 		$1.14M Buy
6,479
+543
+9% +$108K ﹤0.01% 3034
2018
Q3 		$1.34M Sell
5,936
-321
-5% -$51.9K ﹤0.01% 3083
2018
Q2 		$948K Sell
6,257
-68
-1% -$12.4K ﹤0.01% 3274
2018
Q1 		$1.16M Buy
6,325
+6
+0.1% +$1.35K ﹤0.01% 3135
2017
Q4 		$1.35M Buy
6,319
+1,314
+26% +$281K ﹤0.01% 3074
2017
Q3 		$1.07M Buy
5,005
+445
+10% +$87.1K ﹤0.01% 3179
2017
Q2 		$862K Buy
4,560
+3,857
+549% +$756K ﹤0.01% 3334
2017
Q1 		$174K Buy
703
+50
+8% +$12.3K ﹤0.01% 3912
2016
Q4 		$166K Sell
653
-110
-14% -$25.2K ﹤0.01% 3941
2016
Q3 		$155K Buy
+763
New +$94.9K ﹤0.01% 3948

Other funds holding CRBP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon's CRBP Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Corbus Pharmaceuticals (CRBP) in Q2 2026: 45,282 shares worth $425K. The stake represents ﹤0.01% of the portfolio and ranks #3818 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in CRBP as recently as Q1 2025.

Bank of New York Mellon first reported a position in CRBP in Q3 2016 and has held it in 31 quarters since. The position peaked at $2.27M in Q2 2020. 38 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Bank of New York Mellon held 45,282 shares of Corbus Pharmaceuticals worth $425K as of Q2 2026.
  • Corbus Pharmaceuticals was a new Bank of New York Mellon position in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3818 holding.
  • Bank of New York Mellon first reported a position in Corbus Pharmaceuticals in Q3 2016 and has held it in 31 quarters since.
  • Bank of New York Mellon's Corbus Pharmaceuticals position peaked at $2.27M in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.